SARS-CoV-2：从群体免疫到混合免疫。
SARS-CoV-2: from herd immunity to hybrid immunity.
机构信息
Great Ormond Street Institute of Child Health, University College London, London, UK.
出版信息
Nat Rev Immunol. 2022 Jun;22(6):333-334. doi: 10.1038/s41577-022-00725-0.
Abstract
Herd immunity, where a pathogen can no longer efficiently spread in a population, is achieved when a large proportion of the population becomes immune, making the spread of infection from person to person unlikely and protecting those without immunity. Despite the global spread of SARS-CoV-2, the failure of virus- and vaccine-induced immunity to prevent transmission, combined with the emergence of antigenically distinct variants, has made herd immunity to SARS-CoV-2 unachievable thus far. Where does this leave us?
摘要
群体免疫是指当人群中有很大一部分人具有免疫力时，病原体在人群中就无法有效地传播，从而使人与人之间的感染传播不太可能发生，并保护那些没有免疫力的人。尽管 SARS-CoV-2 在全球范围内传播，但病毒和疫苗诱导的免疫未能阻止传播，加上出现了具有不同抗原性的变异株，使得迄今为止无法实现 SARS-CoV-2 的群体免疫。这让我们处于何种境地？
相似文献
1
SARS-CoV-2: from herd immunity to hybrid immunity.SARS-CoV-2：从群体免疫到混合免疫。
Nat Rev Immunol. 2022 Jun;22(6):333-334. doi: 10.1038/s41577-022-00725-0.
2
Challenges in Engendering Herd Immunity to SARS-CoV-2 Infection: Possibly Impossible But Plausibile.引发 SARS-CoV-2 感染群体免疫的挑战：可能不可能但似乎有可能。
Infect Disord Drug Targets. 2022;22(4):e170122200309. doi: 10.2174/1871526522666220117153838.
3
How to Understand Herd Immunity in the Context of COVID-19.如何理解 COVID-19 大流行中的群体免疫。
Viral Immunol. 2021 Apr;34(3):174-181. doi: 10.1089/vim.2020.0195. Epub 2020 Dec 21.
4
The Concept of Classical Herd Immunity May Not Apply to COVID-19.经典群体免疫概念可能不适用于新冠病毒。
J Infect Dis. 2022 Aug 24;226(2):195-198. doi: 10.1093/infdis/jiac109.
5
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.基于 SARS-CoV-2 的免疫原性结构蛋白、宿主免疫反应和群体免疫的 COVID-19 疫苗开发的新见解。
Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949.
6
Reaching Herd Immunity During the SARS-CoV-2 Pandemic: What School Nurses Need to Know.在新冠疫情期间实现群体免疫：学校护士需要了解的内容。
NASN Sch Nurse. 2022 Jan;37(1):13-18. doi: 10.1177/1942602X211044996. Epub 2021 Nov 26.
7
The dilemma of herd immunity for COVID-19.新冠病毒群体免疫的困境。
J Med Virol. 2021 May;93(5):2578-2579. doi: 10.1002/jmv.26768. Epub 2021 Feb 23.
8
The potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant.接种疫苗诱导针对 SARS-CoV-2 B.1.1.7 变异株的群体免疫的潜力。
Euro Surveill. 2021 May;26(20). doi: 10.2807/1560-7917.ES.2021.26.20.2100428.
9
Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program.SARS-CoV-2 暴露 6 个月后社区治疗项目个体的混合和群体免疫。
Sci Rep. 2023 Jan 14;13(1):763. doi: 10.1038/s41598-023-28101-5.
10
COVID-19: individual and herd immunity.COVID-19：个体和群体免疫。
C R Biol. 2021 Jun 21;344(1):7-18. doi: 10.5802/crbiol.41.
引用本文的文献
1
Replication-incompetent VSV-based vaccine elicits protective responses against SARS-CoV-2 and influenza virus.基于水疱性口炎病毒（VSV）的复制缺陷型疫苗可引发针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）和流感病毒的保护性反应。
Sci Adv. 2025 Jan 31;11(5):eadq4545. doi: 10.1126/sciadv.adq4545. Epub 2025 Jan 29.
2
Influencing Canadian young adults to receive additional COVID-19 vaccination shots: the efficacy of brief video interventions focusing on altruism and individualism.促使加拿大青年接受额外的 COVID-19 疫苗接种：以利他主义和个人主义为重点的简短视频干预的效果。
Front Public Health. 2024 Oct 4;12:1414345. doi: 10.3389/fpubh.2024.1414345. eCollection 2024.
3
Anti-SARS-CoV-2 Neutralizing Responses in Various Populations: Use of a Rapid Surrogate Lateral Flow Assay and Correlations with Anti-RBD Antibody Levels.不同人群中抗SARS-CoV-2中和反应：快速替代侧向流动检测法的应用及其与抗RBD抗体水平的相关性
Life (Basel). 2024 Jun 22;14(7):791. doi: 10.3390/life14070791.
4
Bioinformatic analysis of defective viral genomes in SARS-CoV-2 and its impact on population infection characteristics.SARS-CoV-2 缺陷病毒基因组的生物信息学分析及其对人群感染特征的影响。
Front Immunol. 2024 Jan 29;15:1341906. doi: 10.3389/fimmu.2024.1341906. eCollection 2024.
5
Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking.靶向 SARS-CoV-2 刺突糖蛋白四元结构域的抗体通过构象锁定防止病毒受体结合。
Immunity. 2023 Oct 10;56(10):2442-2455.e8. doi: 10.1016/j.immuni.2023.09.003. Epub 2023 Sep 29.
6
Effect of seasonal coronavirus immune imprinting on the immunogenicity of inactivated COVID-19 vaccination.季节性冠状病毒免疫印迹对灭活 COVID-19 疫苗免疫原性的影响。
Front Immunol. 2023 Aug 16;14:1195533. doi: 10.3389/fimmu.2023.1195533. eCollection 2023.
7
Analyzing factors determining vaccination willingness against COVID-19 in Germany 2020.分析2020年德国民众对新冠疫苗接种意愿的决定因素。
Vaccine X. 2023 Jun 30;14:100342. doi: 10.1016/j.jvacx.2023.100342. eCollection 2023 Aug.
8
Nationwide analysis of the impact of COVID-19 in patients with a cardiovascular, oncological or chronic pulmonary disease in the context of an Eastern European country with a low vaccination rate, Bulgaria: March 2020-April 2022.在一个疫苗接种率较低的东欧国家保加利亚，对心血管、肿瘤或慢性肺部疾病患者在 COVID-19 背景下的全国范围分析：2020 年 3 月至 2022 年 4 月。
BMJ Open. 2023 Aug 2;13(8):e068431. doi: 10.1136/bmjopen-2022-068431.
9
SARS-CoV-2 Reinfections in Health-Care Workers, 1 March 2020-31 January 2023.2020 年 3 月 1 日至 2023 年 1 月 31 日期间医护人员中 SARS-CoV-2 再感染情况。
Viruses. 2023 Jul 14;15(7):1551. doi: 10.3390/v15071551.
10
Considerations for vaccinating children against COVID-19.接种 COVID-19 疫苗的注意事项。
BMJ Paediatr Open. 2023 Jul;7(1). doi: 10.1136/bmjpo-2023-001964.
本文引用的文献
1
Effectiveness of BNT162b2 and ChAdOx1 against SARS-CoV-2 household transmission: a prospective cohort study in England.BNT162b2和ChAdOx1对严重急性呼吸综合征冠状病毒2型家庭传播的有效性：英国的一项前瞻性队列研究
Wellcome Open Res. 2023 Nov 2;8:96. doi: 10.12688/wellcomeopenres.17995.2. eCollection 2023.
2
Humoral and cellular immune memory to four COVID-19 vaccines.体液免疫和细胞免疫对四种 COVID-19 疫苗的记忆。
Cell. 2022 Jul 7;185(14):2434-2451.e17. doi: 10.1016/j.cell.2022.05.022. Epub 2022 May 27.
3
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden.具有自然免疫和混合免疫的个体中再次感染SARS-CoV-2和因COVID-19住院的风险：瑞典一项回顾性全人群队列研究
Lancet Infect Dis. 2022 Jun;22(6):781-790. doi: 10.1016/S1473-3099(22)00143-8. Epub 2022 Apr 1.
4
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa.南非出现奥密克戎后，SARS-CoV-2 再感染的风险增加。
Science. 2022 May 6;376(6593):eabn4947. doi: 10.1126/science.abn4947.
5
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.Covid-19 疫苗对奥密克戎（B.1.1.529）变异株的有效性。
N Engl J Med. 2022 Apr 21;386(16):1532-1546. doi: 10.1056/NEJMoa2119451. Epub 2022 Mar 2.
6
Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination.人类 SARS-CoV-2 感染和接种疫苗中的免疫印迹、变体识别广度和生发中心反应。
Cell. 2022 Mar 17;185(6):1025-1040.e14. doi: 10.1016/j.cell.2022.01.018. Epub 2022 Jan 25.
7
Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2.预先存在的聚合酶特异性 T 细胞在 SARS-CoV-2 无血清学阴性中扩增。
Nature. 2022 Jan;601(7891):110-117. doi: 10.1038/s41586-021-04186-8. Epub 2021 Nov 10.
8
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.德尔塔变异株对英国新冠病毒载量及针对新型严重急性呼吸综合征冠状病毒2感染的疫苗效力的影响。
Nat Med. 2021 Dec;27(12):2127-2135. doi: 10.1038/s41591-021-01548-7. Epub 2021 Oct 14.
9
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN).英格兰抗体阳性与抗体阴性医护人员的 SARS-CoV-2 感染率：一项大型、多中心、前瞻性队列研究（SIREN）。
Lancet. 2021 Apr 17;397(10283):1459-1469. doi: 10.1016/S0140-6736(21)00675-9. Epub 2021 Apr 9.
Zotero 插件